Drug Profile

Rilonacept - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals

Alternative Names: ARCALYST; Arcalyst; IL-1-Cytokine-Trap; IL-1-Trap; Interleukin-1 Trap; KPL 914; RGN-303

Latest Information Update: 07 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regeneron Pharmaceuticals
Developer Boston University; Charite - Universitatsmedizin Berlin; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals
Class Anti-inflammatories; Antianaemics; Antirheumatics; Cardiovascular therapies; Recombinant fusion proteins; Skin disorder therapies
Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cryopyrin-associated periodic syndromes; Pericarditis
New Molecular Entity Yes

Marketed Cryopyrin-associated periodic syndromes; Inborn genetic disorders; Pericarditis
Phase II Sarcoidosis; Urticaria
Phase I/II Systemic scleroderma
Discontinued Anaemia; Gout; Juvenile rheumatoid arthritis; Osteoarthritis; Polymyalgia rheumatica; Rheumatoid arthritis

31 Dec 2024 Phase-II clinical trials in Sarcoidosis (SC), prior to December 2024
30 Aug 2024 Efficacy and adverse events data from phase III RHAPSODY trial in Pericarditis presented at the Annual Congress of the European Society of Cardiology (ESC Congress-2024)
04 Jan 2024 Launched for Pericarditis (Recurrent) in Israel (SC) before January 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com